RTOG 0834/EORTC26053_22054, Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CANTON Intergroup trial.
December 17, 2009
Cancer - Brain
Principal Investigator: Eleanor M Walker, MD
The purpose of this study is to determine whether the addition of temozolomide treatment to radiotherapy (concomitant treatment) or the addition of temozolomide treatment after completion of radiotherapy on 5 days out of every 28 days for 12 months (adjuvant treatment) will improve the results of the treatment. This study will find out what effects, good and/or bad, the addition of temozolomide has when it is given at the same time as radiotherapy, after radiotherapy, or both.
Histologically confirmed newly diagnosed anaplastic oligodendroglioma, anaplastic oligoastrocytoma or anaplastic astrocytoma by local diagnosis and absence of combined 1p/19q loss; available tumor material for central 1p/19q assessment, central MGMT promoter methaylation and central pathology review; previous surgery for a low grade tumor is allowed, provided histological confirmation of an anaplastic tumor is present at the time of progression.